Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vaccine Production in Plants Nets Scientist Innovator of the Year 2012

Published: Friday, March 30, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
Innovation could allow quicker vaccine development to combat pandemics.

Professor George Lomonossoff has been named BBSRC Innovator of the Year 2012 for his work with Dr Frank Sainsbury, to develop a system for producing vaccines and pharmaceutical proteins rapidly in plants.

The system could allow vaccines to be produced much more rapidly for emergency vaccination programmes in the face of disease pandemics.

Professor Lomonossoff, of the John Innes Centre in Norwich, which receives strategic funding from BBSRC, and Dr Sainsbury, of Laval University in Canada, received their prize and trophy from Business Secretary, Vince Cable, who spoke at the final in London last night.

Dr Cable said: “I would like to congratulate the winners on their success. Their innovative ideas highlight the vital role that scientific knowledge plays in driving growth in important sectors like healthcare, food, and pharmaceuticals.

“The UK is a world leader in the biosciences and it is vital that we capitalize on this strength to deliver the maximum social and economic benefit. All of the finalists have gone to impressive lengths to ensure that the impacts of their research are felt well beyond the scientific community and this is truly worth celebrating.”

Professor Lomonossoff and Dr Sainsbury’s innovation enables proteins to be produced much more rapidly and at higher levels than has previously been possible in plants.

This is revolutionizing the use of plants as bioreactors and will help make plant-produced proteins a commercial reality.

The system has already been licensed to a number of potential partners in the commercial sector including the biopharmaceutical company Medicago.

Medicago are already using Professor Lomonossoff and Dr Sainsbury’s system as the principal production platform for a number of vaccines and therapeutic proteins currently in development.

Professor Lomonossoff expressed his delight at winning, saying: “You want to hope but you don’t dare. It’s a big surprise; rather like winning an Oscar.”

Professor Lomonossoff also thanked the many people who had helped to make the project a reality.

The judging panel gave the following comment of Professor Lomonosssoff’s innovation: “The panel were impressed by the innovators drive and passion, and speed with which the technology was moved forward. He had thought really hard about what the end customer wanted and was very realistic about the scope of the technology. The judging panel considered that the innovation had the potential to have much wider impact in the future.”

Professor Lomonossoff and Dr Sainsbury also won the prize for the Most Promising Innovator. Two other category prizes - Commercial Innovator and Social Innovator - were won by Professor Jim Murray of Cardiff University and his co-applicant Dr Laurence Tisi of Lumora Ltd, and Professor Russell Foster of the University of Oxford respectively.

Professor Russell Foster of the University of Oxford was awarded the Social Innovator prize for his work to revolutionist our understanding of the eye which has had impacts both in the clinic and further afield.

His findings are having a major impact across society helping, for example, with the design of new lighting systems and the use of natural light in buildings.

Professor Jim Murray of Cardiff University took the Commercial Innovator prize with Dr Laurence Tisi of Kumora Ltd, for their efforts in developing a system, called BART (Bioluminescent Assay in Real-Time), for detecting infectious organisms like bacteria and viruses that can be used almost anywhere. This could dramatically improve healthcare for patients in the developed and developing world.

The Biotechnology and Biological Sciences Research Council (BBSRC) Innovator of the Year Award is a competition designed to recognize and reward scientists who are ensuring that the UK's excellent bioscience research is translated into outcomes that positively affect economic growth and quality of life for everyone.

The award, now in its fourth year, was established with a view to encouraging researchers to consider the potential of their research and take the necessary steps to maximize the social and economic impact of the excellent work they do.

The nine finalists (see 'Notes to editors' section for details) were selected by an independent judging panel to compete in each of the three categories and for the overall prize.

Also speaking at the final was Jeremy Webb, Editor-in-Chief of New Scientist. Offering his congratulations, he said: “I don’t think I’ve come across a better collection of ideas in all my travels with the New Scientist over the past 20 years.”

Dr Celia Caulcott, Director of Innovation and Skills, BBSRC said: "This is the age of bioscience with techniques and technologies advancing at an exciting pace. These advances underpin so much that is so very important in our daily lives, such as food, health and fuel. The bioscience research community can make an enormous difference to mitigating the great challenges we face, enabling food security and life-long well-being, and helping to address climate change. Today's innovations highlight the impact of this potential and the enormous possibilities from bioscience."

Talking about the potential for innovation in Bioscience, Glyn Edwards, Chief Executive, UK BioIndustry Association, said: “The UK is a stunningly good place to do this. There has never been a better time for bioscience.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Way to Improve Antibiotic Production
A discovery has been made which could make it easier to scale up antibiotic production for commercialisation.
Tuesday, June 18, 2013
BBSRC is Major Partner in Europe-wide Synthetic Biology Funding
BBSRC is contributing €3M as a major partner in a new call for research projects in Synthetic Biology.
Tuesday, May 14, 2013
H7N9: A Novel Influenza Virus and it’s Control
Whilst the virus remains as one primarily circulating in birds, breaking this cycle of replication is the only effective response to its control.
Thursday, May 09, 2013
BBSRC Supports Call for Multi-Disciplinary Research Centres in Synthetic Biology
Up to six centres will be funded in two phases; three in this financial year and three next financial year.
Friday, May 03, 2013
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!